Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
View Patent ↗Disclosed herein are methods and compositions of treating cancer, comprising administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a nucleocytoplasmic transport inhibitor. Further described herein are methods of converting a nonpermissive cancer cell to a permissive cancer cell and methods of killing a cancer cell by contacting the cancer cell with a therapeutically effective amount of an oncolytic vims and a nucleocytoplasmic transport inhibitor.
1 . A method of enhancing susceptibility of a cancer cell to infection by an oncolytic virus, comprising contacting the cancer cell to an oncolytic virus and a nucleocytoplasmic transport inhibitor, wherein the nucleocytoplasmic transport inhibitor is Leptomycin B.
2 . A pharmaceutical composition comprising:
a. an oncolytic virus, and
b. a nucleocytoplasmic transport inhibitor, wherein the nucleocytoplasmic transport inhibitor is Leptomycin B.
3 . The pharmaceutical composition of claim 2 , wherein the oncolytic virus is derived from the Poxviridae family.
4 . The pharmaceutical composition of claim 2 , wherein the oncolytic virus is derived from Chordopoxvirinae subfamily or Entomopoxvirinae subfamily.
5 . The pharmaceutical composition of claim 2 , wherein the oncolytic virus is derived from a virus genus of Orthopoxvirus, Cervidpoxvirus, Parapoxvirus, Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus, Yatapoxvirus, Alphaentomopoxvirus, Betaentomopoxvirus , or Gammaentopoxvirus.
6 . The pharmaceutical composition of claim 2 , wherein the oncolytic virus is derived from genus Leporipoxvirus.
7 . The pharmaceutical composition of claim 2 , wherein the oncolytic virus is a myxoma virus (MYXV).